SNCA and Parkinson disease: In this study, we used a mouse transgenic line stably expressing human α-synuclein fused to GFP, which has been widely used to study how PD risk factors or therapeutic compounds affect α-synuclein aggregation and motor impairment caused by α-synuclein dysregulation [73].